A cikin 'yan shekarun nan, maganin kiba da nau'in ciwon sukari na 2 ya sami ci gaba na juyin juya hali. Masu bin GLP-1 agonists masu karɓa (misali, Semaglutide) da agonists dual (misali, Tirzepatide),Retatrutide(LY3437943), auku agonist(GLP-1, GIP, da masu karɓar glucagon), sun nuna ingancin da ba a taɓa ganin irinsa ba. Tare da sakamako mai ban mamaki a cikin raguwar nauyi da haɓakar rayuwa, ana ɗaukarsa azaman yuwuwar maganin ci gaba don cututtukan rayuwa.
Tsarin Aiki
-
GLP-1 kunna mai karɓa: Yana inganta fitar insulin, yana hana ci, yana jinkirta zubar da ciki.
-
Kunna mai karɓar GIP: Yana haɓaka tasirin ragewar glucose na GLP-1, yana haɓaka haɓakar insulin.
-
Kunna mai karɓar Glucagon: Yana haɓaka kashe kuzarin kuzari da metabolism mai.
Haɗin gwiwar waɗannan masu karɓa guda uku suna ba da damar Retatrutide ya zarce magungunan da ke akwai a cikin asarar nauyi da sarrafa glycemic.
Bayanan Gwaji na asibiti (Mataki na II)
A cikin aGwajin Mataki na II tare da marasa lafiya 338 masu kiba/kiba, Retatrutide ya nuna sakamako mai ban sha'awa sosai.
Tebur: Kwatanta Retatrutide vs. Placebo
| Kashi (mg/week) | Matsakaicin Rage Nauyi (%) | Rage HbA1c (%) | Abubuwan Da Ya Shafa |
|---|---|---|---|
| 1 mg | -7.2% | -0.9% | Tashin zuciya, amai mara nauyi |
| 4 mg | -12.9% | -1.5% | Tashin zuciya, rashin ci |
| 8 mg | -17.3% | -2.0% | GI rashin jin daɗi, zawo mai laushi |
| 12 mg | -24.2% | -2.2% | Tashin zuciya, rashin ci, maƙarƙashiya |
| Placebo | -2.1% | -0.2% | Babu gagarumin canji |
Kallon Bayanai (Kwantawar Rage Nauyi)
Taswirar mashaya mai zuwa yana kwatantamatsakaicin rage nauyidaban-daban na Retatrutide idan aka kwatanta da placebo:
Lokacin aikawa: Satumba-16-2025